Apimeds Pharmaceuticals Us, INC Form 4 insider transactions

Apimeds Pharmaceuticals US, Inc. filed an amendment to its 8-K report to declare previous actions by majority stockholders, including director and officer removals, null and void due to contractual violations.

Apimeds Pharmaceuticals US, Inc. has completed a merger with MindWave Innovations Inc., combining its biopharmaceutical pipeline with MindWave's AI-driven Bitcoin treasury and digital asset yield generation, supported by a private investment of up to $120.9 million.

Inscobee Inc. filed an amended Form 4 to clarify its direct and indirect beneficial ownership of Apimeds Pharmaceuticals US, Inc. common stock.

Apimeds Pharmaceuticals US, Inc. Director Bennett Weintraub was granted options to purchase 10,000 shares of common stock at an exercise price of $2.67, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Hankil Yoon was granted 10,000 stock options with an exercise price of $2.67, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Jakap Koo was granted 10,000 stock options with an exercise price of $2.67, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Carol A. O'Donnell was granted 10,000 stock options with a $2.67 exercise price.

Apimeds Pharmaceuticals US, Inc. Director Elona Kogan was granted 10,000 stock options with an exercise price of $2.67, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Elona Kogan was granted 3,000 stock options with an exercise price of $1.92, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Carol A O'Donnell was granted 3,000 stock options with an exercise price of $1.92, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Jakap Koo was granted 3,000 stock options with an exercise price of $1.92, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Bennett Weintraub was granted 3,000 stock options with an exercise price of $1.92, vesting over three years.

Apimeds Pharmaceuticals US, Inc. granted 3,000 stock options to Chairman and CMO Christopher Kim, exercisable at $1.92, with vesting contingent on continued service and stockholder approval.

Apimeds Pharmaceuticals US, Inc. director Hankil Yoon was granted 3,000 stock options with an exercise price of $1.92, vesting over three years.

Apimeds Pharmaceuticals US, Inc. CEO Erik C. Emerson was granted 215,000 stock options with a $1.92 exercise price, vesting over three years.

Inscobee Inc., a 10% owner and director of Apimeds Pharmaceuticals US, Inc., has converted $299,340 in convertible promissory notes into 115,131 shares of common stock, while also amending a previous filing to clarify direct beneficial ownership.

Director Elona Kogan reports acquisition of stock options in Apimeds Pharmaceuticals US, Inc.

Director Hankil Yoon reports acquisition of stock options in Apimeds Pharmaceuticals US, Inc. on May 16, 2025.

Carol A. O'Donnell, a director of Apimeds Pharmaceuticals US, Inc., acquired stock options exercisable for 5,780 shares of common stock.

Christopher Kim, Director and Chairman/CMO of Apimeds Pharmaceuticals US, Inc., reports acquisition of 250,000 shares of common stock.

Erik C. Emerson, CEO of Apimeds Pharmaceuticals US, Inc., reports acquisition of 750,000 shares and 347,279 stock options.

Director Bennett Weintraub acquired stock options for 5,780 shares of Apimeds Pharmaceuticals US, Inc. on May 16, 2025.

Director Jakap Koo reports acquisition of stock options in Apimeds Pharmaceuticals US, Inc.

Director and CMO of Apimeds Pharmaceuticals US, Inc., Christopher Kim, reports the acquisition and disposal of common stock on May 13 and 14, 2025.

Director Jakap Koo reports purchasing 28,500 shares of Apimeds Pharmaceuticals US, Inc. at an average price of $1.99 per share.

Inscobee Inc. reports the conversion of convertible promissory notes into common stock of Apimeds Pharmaceuticals US, Inc. following a qualified financing event.